These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 16781743)
1. Steroidogenic alterations and adrenal androgen excess in PCOS. Doi SA; Al-Zaid M; Towers PA; Scott CJ; Al-Shoumer KA Steroids; 2006 Sep; 71(9):751-9. PubMed ID: 16781743 [TBL] [Abstract][Full Text] [Related]
2. [Exploration of the classification of polycystic ovarian syndrome]. Lin JF; Li X; Zhu MW Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924 [TBL] [Abstract][Full Text] [Related]
3. Adrenal androgen excess and body mass index in polycystic ovary syndrome. Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100 [TBL] [Abstract][Full Text] [Related]
4. Impact of adrenal versus ovarian androgen ratio on signs and symptoms of polycystic ovarian syndrome. Köşüş N; Köşüş A; Kamalak Z; Hızlı D; Turhan NÖ Gynecol Endocrinol; 2012 Aug; 28(8):611-4. PubMed ID: 22296561 [TBL] [Abstract][Full Text] [Related]
5. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576 [TBL] [Abstract][Full Text] [Related]
6. DHEA, DHEAS and PCOS. Goodarzi MO; Carmina E; Azziz R J Steroid Biochem Mol Biol; 2015 Jan; 145():213-25. PubMed ID: 25008465 [TBL] [Abstract][Full Text] [Related]
7. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome? Vural B; Ozkan S; Bodur H J Obstet Gynaecol Res; 2007 Apr; 33(2):166-73. PubMed ID: 17441890 [TBL] [Abstract][Full Text] [Related]
8. Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome. Park HR; Choi Y; Lee HJ; Oh JY; Hong YS; Sung YA Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S233-7. PubMed ID: 17606307 [TBL] [Abstract][Full Text] [Related]
9. Adrenal androgen production capacity remains high up to menopause in women with polycystic ovary syndrome. Puurunen J; Piltonen T; Jaakkola P; Ruokonen A; Morin-Papunen L; Tapanainen JS J Clin Endocrinol Metab; 2009 Jun; 94(6):1973-8. PubMed ID: 19318449 [TBL] [Abstract][Full Text] [Related]
10. Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. Kjøtrød SB; Sunde A; von Düring V; Carlsen SM Fertil Steril; 2009 Feb; 91(2):500-8. PubMed ID: 18304542 [TBL] [Abstract][Full Text] [Related]
11. Body fat composition and distribution in women with polycystic ovary syndrome. Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379 [TBL] [Abstract][Full Text] [Related]
12. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. Toscani M; Migliavacca R; Sisson de Castro JA; Spritzer PM Metabolism; 2007 Jul; 56(7):992-7. PubMed ID: 17570263 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Nácul AP; Andrade CD; Schwarz P; de Bittencourt PI; Spritzer PM Eur J Obstet Gynecol Reprod Biol; 2007 Aug; 133(2):191-6. PubMed ID: 17049715 [TBL] [Abstract][Full Text] [Related]
14. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512 [TBL] [Abstract][Full Text] [Related]
15. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation]. Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992 [TBL] [Abstract][Full Text] [Related]
16. Androgens in polycystic ovary syndrome: the role of exercise and diet. Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064 [TBL] [Abstract][Full Text] [Related]
17. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Kebapcilar L; Taner CE; Kebapcilar AG; Sari I Arch Gynecol Obstet; 2009 Aug; 280(2):187-93. PubMed ID: 19107500 [TBL] [Abstract][Full Text] [Related]
18. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
19. Influence of body mass index on measured and calculated androgen parameters in adult women with Hirsutism and PCOS. Cupisti S; Dittrich R; Binder H; Kajaia N; Hoffmann I; Maltaris T; Beckmann MW; Mueller A Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):380-6. PubMed ID: 17701884 [TBL] [Abstract][Full Text] [Related]
20. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]